v3.26.1
Segment Information - Schedule of Segment Information (Details) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2026
Mar. 31, 2025
Segment Reporting Information [Line Items]    
Revenues $ 563 $ 197
Net loss (3,521) (2,420)
Other Operating Segment [Member]    
Segment Reporting Information [Line Items]    
Revenues 563 197
Other research and development expenses [1] 57 127
Non-program expenses [2] 1,527 1,106
Personnel compensation and related expenses, including share-based compensation 1,789 1,067
Other segment items [3] 53 (691)
Net loss (3,521) (2,420)
Other Operating Segment [Member] | Clinical Trial Studies [Member]    
Segment Reporting Information [Line Items]    
Program expenses [1] 422 758
Other Operating Segment [Member] | Manufacturing Renovocath [Member]    
Segment Reporting Information [Line Items]    
Program expenses [1] $ 236 $ 250
[1] Includes external research expenses, clinical studies, manufacturing including manufacturing and non-recurring engineering costs, professional and consulting, regulatory, and trade shows for 2026.
[2] Includes selling, general and administrative expenses for professional and consulting expenses, audit fees, board fees, legal expenses, insurance expenses, travel, marketing expenses for 2026 and other office expenses.
[3] Includes interest income and interest expense and gain recognized on the fair value of common stock warrant liability.

Major Customers

For the three months ended March 31, 2026 and 2025, five customers, Customers A, B, C, D and E, accounted for more 10% of the Company's total revenue. For the three months ended March 31, 2026, Customers A, B and C accounted for 27.2%, 15.2% and 13.6%, respectively. For the three months ended March 31, 2025, Customers A accounted for 34.8% and Customers D and E each accounted for 26.1%.